Ranbaxy launches two new ARVs in India
Ranbaxy Laboratories Limited (RLL) announced that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India.
Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in daily use packs.
Virolis-E is a compliance pack containing two fixed dose combination tablets of 3TC 150mg & d4T 30/40mg and one tablet of efavirenz 600mg.
Virocomb-E is also a compliance pack and contains two fixed dose combination tablets of 3TC 150mg & AZT 300mg and one tablet of efavirenz 600mg.
Source: Ranbaxy Press Release